Evidence item

Independent coverage reports the 711-patient trial’s null symptom and exercise outcomes with generally acceptable safety. DIRECT_TEXT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 16785

Source: Mitiperstat Misses Endpoints in HFpEF Trial · locator {} · excerpt hash sha256:502fedf16e6548503f33d21098b09098320d440534e7b100caf2ca1326ff90f2

A 711-patient phase 2b trial found the myeloperoxidase inhibitor mitiperstat was safe and well tolerated but failed to improve symptoms or exercise capacity in heart failure with preserved ejection fraction.